Investors who take an interest in AN2 Therapeutics, Inc. (NASDAQ:ANTX) should definitely note that the Independent Director, Robin Readnour, recently paid US$1.07 per share to buy US$213k worth of the stock. That certainly has us anticipating the best, especially since they thusly increased their own holding by 64%, potentially signalling some real optimism.

The Last 12 Months Of Insider Transactions At AN2 Therapeutics

The Co-Founder & Chairman of the Board, Joseph Zakrzewski, made the biggest insider sale in the last 12 months. That single transaction was for US$1.9m worth of shares at a price of US$19.11 each. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. The silver lining is that this sell-down took place above the latest price (US$1.34). So it may not shed much light on insider confidence at current levels. The only individual insider seller over the last year was Joseph Zakrzewski.

Happily, we note that in the last year insiders paid US$288k for 275.00k shares. But insiders sold 100.00k shares worth US$1.9m. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).

Does AN2 Therapeutics Boast High Insider Ownership?

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 6.1% of AN2 Therapeutics shares, worth about US$2.2m, according to our data. Whilst better than nothing, we're not overly impressed by these holdings.

So What Do The AN2 Therapeutics Insider Transactions Indicate?

The recent insider purchases are heartening. However, the longer term transactions are not so encouraging. Neither the level of insider ownership, nor the transactions over the last twelve months inspire us, but we think the recent buying is positive. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing AN2 Therapeutics. Every company has risks, and we've spotted 3 warning signs for AN2 Therapeutics (of which 1 is significant!) you should know about.

But note: AN2 Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.